The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
FDA Places Clinical Hold on 3 Pembrolizumab Myeloma Trials
July 6th 2017The FDA has placed a clinical hold on the phase III KEYNOTE-183 and KEYNOTE-185 pembrolizumab (Keytruda) trials and ordered the discontinuation of the lenalidomide/dexamethasone/pembrolizumab arm of the KEYNOTE-023 trial in patients with multiple myeloma.
Expert Discusses Dramatic Impact of Immunotherapy on NSCLC Paradigm
July 6th 2017Melissa Johnson, MD, discusses the impact of immunotherapy for patients with non-small cell lung cancer—those with both high and low levels of PD-L1 expression—and how the treatment and the role of PD-L1 will continue to progress in the coming years.
Blood-Based Assays Are Addition, But Not Replacement for Lung Tissue Biopsies
July 5th 2017Leora Horn, MD, MSc, discusses the utility of blood-based biomarkers, how they have transformed treatment approaches for patients with non-small cell lung cancer, and the ongoing work currently being done with them.
FDA Approves First Flow Cytometry-Based Diagnostic for Blood Cancer Detection
June 30th 2017The FDA has approved ClearLLab multicolor reagents (T1, T2, B1, B2, M) for the detection of chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms.
Future of Immunotherapy for GU Malignancies Goes Beyond Oncology Department
June 28th 2017Costas Lallas, MD, discusses the current role of immunotherapy for patients with genitourinary cancers, the potential for immunotherapy in combination with chemotherapy, and how the rise of immunotherapy affects all providers treating patients with these malignancies.
Frontline Brentuximab Vedotin Extends PFS in Hodgkin Lymphoma
June 26th 2017Frontline brentuximab vedotin (Adcetris) was associated with improved progression-free survival compared with standard chemotherapy in patients with advanced classical Hodgkin lymphoma, according to results from the phase III ECHELON-1 clinical trial.
Frontline Pembrolizumab Approval Leaves Questions for Later Lines in Bladder Cancer
June 23rd 2017Jorge Garcia, MD, discusses how the field of bladder cancer has transformed with the FDA approval of pembrolizumab, and how oncologists should choose between 5 checkpoint inhibitors now available for the second-line setting and beyond.
Ribociclib Recommended for EU Approval in Frontline HR+/HER2- Breast Cancer
June 23rd 2017The Committee for Medicinal Products for Human Use, a part of the European Medicines Agency, recommended approval of ribociclib (Kisqali) for use in combination with an aromatase inhibitor as a first-line treatment for postmenopausal women with hormone receptor-positive /HER2-negative locally advanced or metastatic breast cancer.
Aldoxorubicin Improves PFS in Advanced Soft Tissue Sarcoma
June 23rd 2017Aldoxorubicin was associated with superior progression-free survival compared with standard chemotherapy regimens and may be a viable treatment alternative for some patients with relapsed or refractory soft tissue sarcomas, according to results from a phase III international study.